New York, NY -- (SBWIRE) -- 05/11/2017 -- Sarcopenia which results in the decrease of lean muscle mass when the person reaches age thirty or above, she or he could expect the gradual loss of muscle tissues due to increasing aging altering the level of activity and also affecting the quality of life. Aging leads to change in metabolic activity which includes the decrease in synthesis of muscle protein and little change in the degradation. Sarcopenia affects the tissue turnover, and muscle repair capacity decreased with age. This is due to the increasing resistance to the insulin as well as increased percentage of body fat mass and a decrease in basal metabolic rate. All this leads to lower hormone excretion, lower physical activity, chronic inflammation and nutritional deficits.

In older people Sarcopenia is identified in three stages: loss of muscle mass known as presarcopenia, loss of muscle which leads to either loss in physical performance or strength and called as Sarcopenia, severe Sarcopenia involves both losses of physical performance and strength. According to the journal of sports health in 2014, it reported that after 70 years of age 0.5% to 1.0% loss of muscle mass occur per year and when compared to men and women, a 4.7% loss in men and 3.7% decrease in women per decade. To fight against the symptoms of Sarcopenia an individual has to work out which includes weight bearing and strength building exercises routinely that build endurance.

Sarcopenia Treatment Market: Drivers and Restraints

Increasing aging and obese population is the prime factor responsible for the progress of Sarcopenia Treatment market. Another factor which is creating the positive impact on of Sarcopenia Treatment market is the fact that there is no permanent cure for the Sarcopenia. Therefore patients suffering from this particular syndrome and its associated conditions have to depend on strength building and weight bearing exercise, supplements, and nutritional diet to obtain relief., this is expected to fuel the growth of the Sarcopenia Treatment market. Furthermore, factors such as R&D stimulation through government policies, changes in disease management, etc. are anticipated to promote the growth of the Sarcopenia Treatment market over the forecast period. However, no availability of promising drug in late pharmaceutical firms pipelines is expected to hamper the growth of the Sarcopenia Treatment market during this time.

Sarcopenia Treatment Market: Overview

Sarcopenia treatment market is projected to grow in forecast period due to increase in the rate of obesity worldwide which is one of the reasons for Sarcopenia as it disturbs the metabolic rate of the body. According to NIH, More than one-third (35.7 percent) of adults are considered to be obese. More than 1 in 20 (6.3 percent) have extreme obesity. Almost 3 in 4 men (74 percent) are deemed to be overweight or obese. The prevalence of obesity is similar for both men and women (about 36 percent). Currently, competitive environment of Sarcopenia treatment comprises of the only off-label and generic drugs such as estrogen, testosterone, and others growth hormones. Recently, pharmaceutical firm's pipeline has no promising drugs in the later stages for the treatment of Sarcopenia treatment. The pharmaceutical companies are also developing therapies for patients of Sarcopenia.

Sarcopenia Treatment Market: Region-wise Outlook

A geographic condition regarding for Intubation market, it has been segmented into five broad regions: North America, Latin America, Europe, and Asia-Pacific excluding Japan, and the Middle East & Africa. North America, followed by Europe, has the largest market for Sarcopenia Treatment due to affordability and accessibility of expensive tests for Sarcopenia Treatment and innovations in drug therapies in this region. Growing demographics and economies in the developing countries such as India and China is expected to lead the growth Sarcopenia Treatment market in Asia. Also, the rise in awareness about Sarcopenia Treatment and increasing research activities for developing Sarcopenia Treatment drugs in the region are also expected to offer the new opportunity to Sarcopenia Treatment market.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/15694

Sarcopenia Treatment Market: Key Market Participants

Some of the Major Key players in the Sarcopenia Treatment market like GlaxoSmithKline, GTX, Inc., Five Prime Therapeutics, Inc are focused on developing selective androgen receptor modulator (SARM), which is a new class of drugs for the chronic Sarcopenia. Radius Health, Inc. which has received the patent on its SARM.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/15694